Spotlighting Vitiligo: New Innovations to be Presented at RAVE 2024

The previous Revolutionizing Atopic Dermatitis annual meeting has had a recent upgrade to the Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) meeting to include 2 new disease states of alopecia areata and vitiligo. In an interview with Dermatology Times, Nanette Silverberg, MD, chair of the Revolutionizing Vitiligo (ReV) congress within RAVE, chief of pediatric dermatology for the Mount Sinai Health System, and site director of pediatric and adolescent dermatology at Mount Sinai West and Mount Sinai Beth Israel, shares why she believes the inclusion of vitiligo this year helps to serve clinicians looking for a well-rounded education that encompasses multiple disease states.

“Dr Jonathan Silverberg is running the atopic dermatitis meeting, or RAD, which has been quite successful and always has this unique mixture of new and older topics blended so that you get the basic science mixed with what's coming down the pipeline. I'm trying to do that with ReV as well to give people a snapshot of where clinical practice is now and where it's headed, and what the opportunities will be for our patients as time moves on,” said Silverberg.

The ReV portion of the conference begins with a keynote lecture from Dr Carolyn Poole, PhD, on the microbiome in vitiligo.

“Dr Carolyn Poole, who is an exceptional research scientist in Chicago, has been devoted to dermatologic diseases for over 2 decades. It's really important that we have in this field people who have been very devoted and have helped develop new scientific concepts. Her speech will start off with the discussion of the microbiome in relationship to vitiligo, and I think that's going to be something that as time goes by, it's going to become more and more important for inflammatory skin disease as we have greater ability to see those connections and identify pathways for prevention or improvement using newer therapeutics,” continued Silverberg.

Other key topics from ReV will include the current pathogenesis of vitiligo, on- and off-label topical therapeutics to consider, recent advances in devices for vitiligo, and more.

In her presentations, Silverberg will discuss on- and off-label topical therapeutics that can be used for vitiligo, including the FDA-approved ruxolitinib. Silverberg will also present her best tips for clinical excellence in a practice that sees vitiligo patients to make patients feel welcomed and understood.

“As physicians, it's hard to get really practical, good data in a short time period. With RAVE, you're getting 3 hours of vitiligo, 3 hours of alopecia areata, and 4 hours of atopic dermatitis, and then the next day more atopic dermatitis. But you can basically, in a day, really, learn the deepest aspects of the condition and be able to follow these disease states,” concluded Silverberg.

For live daily email updates from RAVE, subscribe to our eNewsletter.